Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.5K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.5K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

225
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient travel burden and postoperative outcomes after lumbar fusion.

North American Spine Society journal·2026
Same author

TMD and Bruxism as Expressions of Central Regulatory State: The Functional Occlusion Regulated Model (FORM).

Journal of clinical medicine·2026
Same author

State Expansions in Medicaid Financial Assistance for Low-Income Medicare Beneficiaries: Changes in Enrollment and Use.

Health services research·2026
Same author

Medicaid Retention After Transition to Medicare Among Adults With Expansion Coverage.

JAMA network open·2026
Same author

Feasibility and acceptability of virtual reality use during intrauterine device procedures: a London-based health service evaluation.

BMJ sexual & reproductive health·2026
Same author

Inferring Rheumatoid Arthritis Disease Activity Status From the Electronic Health Records Across Health Systems.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Related Experiment Video

Updated: Aug 27, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

326

A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18F-MK-6240 PET.

John P Seibyl1,2, Jonathan M DuBois3, Annie Racine3

  • 1Institute for Neurodegenerative Disorders, New Haven, Connecticut; jpseibyl@seibyl.com.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|September 29, 2022
PubMed
Summary

A new visual assessment method for 6-(fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine (18F-MK-6240) Positron Emission Tomography (PET) scans effectively identifies tau deposition in Alzheimer's disease (AD) trials. This method shows high reader agreement and accuracy, supporting its use in clinical drug development.

Keywords:
Alzheimer diseaseMK-6240PETneurologytau proteinopathies

More Related Videos

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
09:58

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

7.7K
Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

10.2K

Related Experiment Videos

Last Updated: Aug 27, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

326
Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
09:58

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

7.7K
Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

10.2K

Area of Science:

  • Neuroimaging
  • Nuclear Medicine
  • Alzheimer's Disease Research

Background:

  • Positron Emission Tomography (PET) imaging of tau protein deposition in vivo is crucial for Alzheimer's disease (AD) drug development.
  • 6-(fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine (18F-MK-6240) is a highly selective radiotracer for neurofibrillary tangles with favorable brain penetration and kinetics.
  • A standardized visual assessment method is needed to evaluate tauopathy severity and regional distribution from 18F-MK-6240 PET scans.

Purpose of the Study:

  • To develop and validate a visual assessment method for characterizing brain tau deposition using 18F-MK-6240 PET imaging.
  • To assess the overall and regional tauopathy burden and identify specific tau binding patterns indicative of AD.

Main Methods:

  • 102 participants' 18F-MK-6240 PET scans were reviewed by an expert nuclear medicine physician to establish visual assessment patterns.
  • The developed visual read method was tested on a separate cohort of 102 participants with two additional trained readers.
  • Visual read outcomes were compared against semiquantitative SUV ratio assessments and clinical diagnoses.

Main Results:

  • The visual assessment method demonstrated high interreader agreement (94% for overall positivity/negativity, 74.3% for regional binary outcomes).
  • The method achieved good sensitivity (73%-79%) and excellent specificity (91%-93%) for detecting tau deposition compared to clinical diagnosis.
  • Visually derived ratings of regional tau involvement strongly correlated with average SUV ratios in cortical regions (r = 0.73, P < 0.0001).

Conclusions:

  • A visual read algorithm for 18F-MK-6240 PET was successfully developed, enabling determination of scan positivity and regional tau deposition.
  • The algorithm exhibits strong interreader concordance and robust diagnostic performance, supporting its utility in clinical trials.
  • This validated visual assessment tool aids in evaluating tau pathology and can be instrumental in Alzheimer's disease drug development.